ANIXA BIOSCIENCES, INC.
3150 Almaden Expressway, Suite 250
San Jose, CA 95118
September 15, 2022
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attn: Tyler Howes
|Re:||Anixa Biosciences, Inc.|
|Registration Statement on Form S-3|
|Filed September 9, 2022, as amended|
|File No. 333-267369|
Dear Mr. Howes:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anixa Biosciences, Inc., hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. EST on Monday, September 19, 2022, or as soon as thereafter practicable.
|Very truly yours,|
|/s/ Dr. Amit Kumar|
|Dr. Amit Kumar|
|Chairman and Chief Executive Officer|
|cc:||Ellenoff Grossman & Schole LLP|